Navigation Links
CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011
Date:4/19/2011

er and glioblastoma.

CureFAKtor recently received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options, and is planning a Phase I clinical study in 2012.

"Focal Adhesion Kinase protein binding inhibitors, such as CFAK-C4, represent a promising area of research as FAK is expressed at extremely high levels in solid cancer tumors and serves as a survival mechanism by signaling tumor growth, invasion and metastasis," said H. Shep Wild.  "We have strong ties to the University of Florida Shands Cancer Center and we look forward to progressing this important research in order to help cancer patients."

CureFAKtor CFAK-C4 Research Results

CureFAKtor recently presented preclinical research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.  

In a poster presentation, CureFAKtor reported that the study pinpointed the site of interaction of VEGFR-3 and FAK to create small molecule drugs capable of disrupting signaling and causing death of pancreatic cancer cells.  CureFAKtor's lead compound, CFAK-C4, reduced tumor growth in vivo in mouse pancreatic cancer cells by up to 60 percent, and CFAK-C4 combined with chemotherapy drug gemcitabine had a synergistic effect and led to 80 percent pancreatic cancer tumor reduction.  

The study also found that CFAK-C4 combined with gemcitabine had a prolonged effect on pancreatic tumor growth.  Two weeks after treatment, the tumor size in the previously treated group was approximately 75 percent smaller than
'/>"/>

SOURCE CureFAKtor Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the ... their 2nd generation cell therapy POD® design. The 2nd generation portfolio not only ... a new POD® design. , “G-CON first offered our miniPOD CT product ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a ... Label Guide . To align chemical container labeling with OSHA’s updated Hazard Communication ... label components, an example of an accurate label, and pictogram uses and meanings. ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Brady Announces a New GHS Label Guide 2
... LEXINGTON, Mass., Nov. 25 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... fiscal year and the three-month period ended September,30, 2008. ... beginning,at 9:00 am eastern time (details follow below). , ... consolidated revenues of $77.8 million,an increase of 18% from fiscal ...
... Md., Nov. 25 EntreMed, Inc. (Nasdaq: ... the treatment of cancer and inflammatory diseases, announced today ... NYSSA 2008 Biotech and Specialty Pharmaceuticals Industry Conference, to ... New York, December 2, 2008. Dane R. Saglio, ...
... 24 Terumo Heart, Inc. is pleased to,announce the ... Executive,Officer (C.E.O.) and President, effective immediately. "With its innovative,mag-lev ... role in,the future treatment of heart failure. I am ... U.S. Pivotal trials in up to 40 clinical sites,and ...
Cached Biology Technology:Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 2Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 3Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 4Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 5Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 6Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 7Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 8Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 9Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 10Indevus Pharmaceuticals Announces Fiscal 2008 Year End and Fourth Quarter Results 11EntreMed to Present at the New York Society of Security Analysts Industry Conference 2Terumo Heart Announces Appointment of William Pinon to Chief Executive Officer and President 2
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... Exceptionally long heat waves and other hot events could become ... according to a new study by Stanford University climate scientists. ... experiments, we see a clear emergence of much more intense, ... said Noah Diffenbaugh, an assistant professor of environmental Earth system ...
... you leave the pediatrician,s office if your child has ... different treatment. A novel application for applying DNA ... quickly and more accurately determine what,s causing a patient,s ... Mark R. Hartman, a Cornell University PhD candidate in ...
... Eurofins MWG Operon, an expert in next generation sequencing ... complex analysis and interpretation of such NGS data, announce ... to offer state-of-the art solutions for comprehensive genome analysis ... cooperate with a partner offering such a high level ...
Cached Biology News:Heat waves could be commonplace in the US by 2039, Stanford study finds 2Heat waves could be commonplace in the US by 2039, Stanford study finds 3Heat waves could be commonplace in the US by 2039, Stanford study finds 4Instant testing for sore throats wins CIMIT prize 2Instant testing for sore throats wins CIMIT prize 3Instant testing for sore throats wins CIMIT prize 4